Tomas Jörgen Eriksson

Tomas Jörgen Eriksson founded Preelumina AB in 2008, where he is working as Chief Executive Officer from 2008 and Guard Therapeutics International AB in 2008, where he worked as Chief Executive Officer from 2008 to 2019.
Mr. Eriksson also currently works at Sinntaxis AB, as Chief Executive Officer from 2019, Omnio AB, as Chairman, Kombinator Affärsutveckling AB, as Director from 2008, Swede Unipharma AB, as Director, and ProstaLund AB, as Independent Director from 2023.
Mr. Eriksson also formerly worked at Lund University Bioscience AB, as Chief Executive Officer, Preelumina Diagnostics AB, as Chairman & Chief Executive Officer, Merozyne Therapeutics AB, as Chairman, WC Likvid AB, as Director, Nordic Bioscience A, as Sales Director from 2001 to 2004, Sista versen 26366 AB, as Director, Finja Five AB, as Director, Enorama Pharma AB, as Independent Director, Termino C 2436 AB, as Director, Magle AB, as Director-Sales & Marketing, Magle Life Sciences AB, as Director-Sales & Marketing, and Gambro AB, as Area Manager.
Mr. Eriksson received his undergraduate degree from the University of Lund.